Literature DB >> 26129649

The effect of timing of antiretroviral therapy on CD4+ T-cell reconstitution in the intestine of HIV-infected patients.

K Allers1, A Puyskens1, H-J Epple1, D Schürmann2, J Hofmann3, V Moos1, T Schneider1.   

Abstract

Whether and to what extent gut mucosal CD4(+) T cells of HIV-infected patients can be restored by combination antiretroviral therapy (cART) is not yet fully resolved. We studied absolute numbers, differentiation, and activation of mucosal CD4(+) T cells at different stages of HIV infection and assessed the effect of timing of cART initiation on this cell population. Mucosal CD4(+) T-cell numbers were severely reduced at all stages of chronic infection, but normal in patients with acute infection. In patients with initiation of cART during chronic HIV infection, mucosal CD4(+) T cells restored to less than half of the numbers in controls. However, in patients who initiated cART during acute HIV infection, mucosal CD4(+) T-cell numbers were fully preserved and markers of microbial translocation and inflammation reversed to normal. The proportion of mucosal effector memory CD4(+) T cells normalized only if cART was initiated at >350 CD4(+) T cells per μl blood but not with delayed treatment. In conclusion, mucosal CD4(+) T-cell numbers can be preserved if cART is initiated in acute HIV infection. In chronically HIV-infected patients, early cART improves mucosal CD4(+) T-cell differentiation but cannot prevent the persistent lack of total CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26129649     DOI: 10.1038/mi.2015.58

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  47 in total

Review 1.  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.

Authors:  Steven G Deeks; Andrew N Phillips
Journal:  BMJ       Date:  2009-01-26

2.  Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Authors:  Gilbert R Kaufmann; Hansjakob Furrer; Bruno Ledergerber; Luc Perrin; Milos Opravil; Pietro Vernazza; Matthias Cavassini; Enos Bernasconi; Martin Rickenbach; Bernard Hirschel; Manuel Battegay
Journal:  Clin Infect Dis       Date:  2005-06-24       Impact factor: 9.079

3.  Impaired CD4+ T-cell restoration in the small versus large intestine of HIV-1-positive South Africans receiving combination antiretroviral therapy.

Authors:  Edana Cassol; Susan Malfeld; Phetole Mahasha; Robert Bond; Tomas Slavik; Chris Seebregts; Guido Poli; Sharon Cassol; Schalk W van der Merwe; Theresa Rossouw
Journal:  J Infect Dis       Date:  2013-06-06       Impact factor: 5.226

4.  Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses.

Authors:  M Macal; S Sankaran; T-W Chun; E Reay; J Flamm; T J Prindiville; S Dandekar
Journal:  Mucosal Immunol       Date:  2008-09-10       Impact factor: 7.313

5.  Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients.

Authors:  H-J Epple; T Schneider; H Troeger; D Kunkel; K Allers; V Moos; M Amasheh; C Loddenkemper; M Fromm; M Zeitz; J-D Schulzke
Journal:  Gut       Date:  2008-10-20       Impact factor: 23.059

6.  Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets.

Authors:  Taheri Sathaliyawala; Masaru Kubota; Naomi Yudanin; Damian Turner; Philip Camp; Joseph J C Thome; Kara L Bickham; Harvey Lerner; Michael Goldstein; Megan Sykes; Tomoaki Kato; Donna L Farber
Journal:  Immunity       Date:  2012-12-20       Impact factor: 31.745

7.  Effect of age on the CD4⁺ T-cell impairment in HIV-infected persons without and with cART.

Authors:  Kristina Allers; Diana Bösel; Hans-Jörg Epple; Heiko Karcher; Wolfgang Schmidt; Désirée Kunkel; Anika Geelhaar-Karsch; Katina Schinnerling; Verena Moos; Thomas Schneider
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

8.  Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels.

Authors:  E J Ciccone; S W Read; P J Mannon; M D Yao; J N Hodge; R Dewar; C L Chairez; M A Proschan; J A Kovacs; I Sereti
Journal:  Mucosal Immunol       Date:  2009-12-02       Impact factor: 7.313

9.  Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.

Authors:  Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Amir Horowitz; Arlene Hurley; Christine Hogan; Daniel Boden; Paul Racz; Martin Markowitz
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  21 in total

Review 1.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  Intestinal CD4 Depletion in HIV / SIV Infection.

Authors:  Ronald S Veazey
Journal:  Curr Immunol Rev       Date:  2019

Review 3.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 4.  Tissue issues: mucosal T-cell responses in HIV-1 infection.

Authors:  Barbara L Shacklett; April L Ferre; Brenna E Kiniry
Journal:  Curr Opin HIV AIDS       Date:  2019-03       Impact factor: 4.283

5.  Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.

Authors:  Brendan M Ottemann; Austin J Helmink; Wenting Zhang; Insiya Mukadam; Christopher Woldstad; James R Hilaire; Yutong Liu; JoEllyn M McMillan; Benson J Edagwa; R Lee Mosley; Jered C Garrison; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  Biomaterials       Date:  2018-09-14       Impact factor: 12.479

6.  Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy.

Authors:  Talia Sainz; Sergio Serrano-Villar; Surinder Mann; Zhong-Min Ma; Netanya S Utay; Corbin G Thompson; Tae-Wook Chun; Angela D Kashuba; Basile Siewe; Anthony Albanese; Paolo Troia-Cancio; Elizabeth Sinclair; Anoma Somasunderam; Tammy Yotter; Santiago Moreno; Richard B Pollard; Alan Landay; Christopher J Miller; David M Asmuth
Journal:  AIDS       Date:  2019-12-01       Impact factor: 4.177

7.  Symptoms and Comorbidities Differ Based on Race and Weight Status in Persons with HIV in the Northern United States: a Cross-Sectional Study.

Authors:  Kierra R Butler; Faye R Harrell; Bridgett Rahim-Williams; Jeffrey M Robinson; Xuemin Zhang; Adwoa Gyamfi; Judith A Erlen; Wendy A Henderson
Journal:  J Racial Ethn Health Disparities       Date:  2022-03-10

8.  A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma.

Authors:  Marta Epeldegui; Larry Magpantay; Yu Guo; Gordana Halec; William G Cumberland; Priscilla K Yen; Bernard Macatangay; Joseph B Margolick; Anne F Rositch; Steven Wolinsky; Otoniel Martinez-Maza; Shehnaz K Hussain
Journal:  AIDS       Date:  2018-04-24       Impact factor: 4.632

Review 9.  Evolution and Diversity of Immune Responses during Acute HIV Infection.

Authors:  Samuel W Kazer; Bruce D Walker; Alex K Shalek
Journal:  Immunity       Date:  2020-11-17       Impact factor: 31.745

Review 10.  Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era.

Authors:  Wei Cao; Vikram Mehraj; Daniel E Kaufmann; Taisheng Li; Jean-Pierre Routy
Journal:  J Int AIDS Soc       Date:  2016-03-03       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.